Using mouse models of PCa we found that the platin-based DNA-crosslinker oxaliplatin (Oxali) potentiates immune rejection of autochthonous or engrafted tumors after genetic or pharmacological depletion of PD-L1–expressing immunosuppressive IgA+ plasmocytes, which cause CTL exhaustion (22). This evidence concerns the gene CD274 and posterior cortical atrophy.